Melanoma-associated antigen 1 and 2 (MAGE-A1/A2)

Melanoma-associated antigen 1 (MAGE-A1) and Melanoma-associated antigen 2 (MAGE-A2) are members of the MAGE-A subfamily of cancer-testis antigens (CTAs) [1, 2]. These proteins are characterized by their restricted expression in the testis and placenta of healthy individuals but are frequently re-expressed in various malignancies, including melanoma, non-small cell lung cancer, and multiple myeloma [13, 16]. Biologically, MAGE-A1 and MAGE-A2 function as scaffolds for E3 ubiquitin ligases, such as TRIM28, and can suppress the activity of the tumor suppressor p53 by recruiting histone deacetylases (HDACs), thereby promoting tumor cell survival and resistance to apoptosis [4, 9, 14]. Due to their high tumor specificity and immunogenicity, MAGE-A1 and MAGE-A2 are attractive targets for cancer immunotherapy [2, 10]. Current therapeutic strategies include T-cell receptor (TCR)-engineered T-cell therapies (e.g., TK-8001, IMA202, TSC-204) and therapeutic peptide vaccines, often used in combination with epigenetic modifiers like decitabine to enhance antigen expression [18, 20, 25, 27]. However, the high homology between MAGE family members poses a risk of off-target toxicity, as seen in previous trials where cross-reactivity with MAGE-A12 in the brain led to severe neurological adverse events [5, 33, 34].

Other names

MAGE1MAGE2MAGE-A1MAGE-A2CT1.1CT1.2Melanoma antigen family A 1Melanoma antigen family A 2

Immunotherapy targeting HLA-presented peptides on tumor cells; Epigenetic induction of antigen expression via DNA demethylation or histone deacetylase inhibition.